Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma. - Farace, F.; Mathiot, C.; Brandely, M.; Tursz, T.; Dorval, T.; Pouillart, P.; Triebel, F.; Hercend, T.; Fridman, W. H. (Clinical & Experimental Immunology, 1990)